Answers are grounded in this paper and cite their sources.
Aducanumab selectively targets aggregated forms of amyloid beta (Aβ), a neuropathological hallmark of Alzheimer's disease (AD).
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: